Leonardo Tjahjono, MD, FAAD, a clinical dermatologist at George Washington University in Washington, DC, discusses dosing regimens for spesolimab (Spevigo) every 4 weeks vs 12 weeks in generalized pustular psoriasis (GPP) and how the efficacy of this treatment varies with those schedules. He notes that clinical trials demonstrated this treatment to be effective in patients regardless of disease duration and describes his practice of extending dosing intervals to every 8 weeks, if possible. The trials showed 4-week dosing to be more effective than the 12-week dosing, with the latter showing no statistical significance over placebo. He mentions a few cases where severe flares were managed with a single 900-mg intravenous dose, maintaining clearance for 6 months.
Topics Covered
- Effectiveness of treatment across disease durations
- Comparison of dosing frequencies
- Challenges and considerations in the treatment of GPP
Explore Related Resources
Scott Worswick, MD: Dosing Strategies for Treating Generalized Pustular Psoriasis
James Song, MD, FAAD: Assessing Systemic GPP Treatment With Targeted Therapy
